M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders

Katerina Zavitsanou1, Andrew Katsifis, Yinghua Yu

  • 1Radiopharmaceuticals R&D, Australian Nuclear Science and Technology Organisation (ANSTO), PMB 1, Menai, Sydney, NSW 2234, Australia. kza@ansto.gov.au

Insights

This study found no changes in M2/M4 muscarinic receptors in the anterior cingulate cortex of individuals with schizophrenia, major depression, or bipolar disorder. Previous research implicated M1 receptors in schizophrenia, suggesting M1, not M2, involvement.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Previous studies indicated reduced M1/M4 muscarinic receptor binding in the anterior cingulate cortex (ACC) in schizophrenia.
  • This reduction was not observed in major depression or bipolar disorder.

Purpose of the Study:

  • To investigate M2/M4 muscarinic receptor binding in the ACC using [(3)H]AF-DX 384.
  • To examine these receptors in patients with schizophrenia, bipolar disorder, and major depression.

Main Methods:

  • Quantitative autoradiography was employed to measure [(3)H]AF-DX 384 binding in post-mortem ACC tissue.
  • The study included 15 cases each of schizophrenia, bipolar disorder, major depression, and controls.

Main Results:

  • No significant differences in [(3)H]AF-DX 384 binding were found between the four diagnostic groups.
  • Binding was higher in males than females and decreased with tissue storage time.
  • In schizophrenia, earlier age of onset correlated with higher binding; in depression, females had lower binding than males.

Conclusions:

  • The findings do not support alterations in M2/M4 receptors in the ACC in schizophrenia or affective disorders.
  • This reinforces the hypothesis of cortical M1 receptor involvement in schizophrenia pathology and treatment, rather than M2 receptors.

Related Concept Videos

Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...